Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

221
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
221
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

222
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
222
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

190
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
190
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

267
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
267
Hepatic Portal System01:21

Hepatic Portal System

5.7K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
5.7K
Second Order systems II01:18

Second Order systems II

398
In an underdamped second-order system, where the damping ratio ζ is between 0 and 1, a unit-step input results in a transfer function that, when transformed using the inverse Laplace method, reveals the output response. The output exhibits a damped sinusoidal oscillation, and the difference between the input and output is termed the error signal. This error signal also demonstrates damped oscillatory behavior. Eventually, as the system reaches a steady state, the error diminishes to zero.
398

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply to: "Fatigue is a symptom of clinical importance in patients with primary sclerosing cholangitis (SOMA.LIV)".

Journal of hepatology·2024
Same author

Knowledge about metabolic dysfunction-associated steatotic liver disease among the medical professionals from countries in the MENA region.

Annals of hepatology·2024
Same author

Health-related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebo-controlled phase III study of resmetirom (MGL-3196) in patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis.

Hepatology (Baltimore, Md.)·2024
Same author

Best buy interventions to address the burden of steatotic liver disease.

The lancet. Gastroenterology & hepatology·2024
Same author

Changes in mortality due to Chronic Liver Diseases (CLD) during the COVID-19 pandemic: Data from the United States' National Vital Statistics System.

PloS one·2024
Same author

Association of food insecurity with MASLD prevalence and liver-related mortality.

Journal of hepatology·2024

Related Experiment Video

Updated: Jan 27, 2026

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K

Hepatitis C Infection: A Systemic Disease

Zobair M Younossi1

  • 1Betty and Guy Beatty Center for Integrated Research, Inova Health System, 3300 Gallows Road, Falls Church, VA 22042, USA; Department of Medicine, Center for Liver Disease, Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA 22042, USA.

Clinics in Liver Disease
|July 11, 2017
PubMed
Summary
This summary is machine-generated.

Hepatitis C virus (HCV) infection causes systemic disease with liver and other complications. A comprehensive view of HCV

Keywords:
Extrahepatic complicationsHepatic complicationsHepatitis C virus

More Related Videos

Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection
11:14

Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection

Published on: November 7, 2018

18.8K
Monitoring of Systemic and Hepatic Hemodynamic Parameters in Mice
16:09

Monitoring of Systemic and Hepatic Hemodynamic Parameters in Mice

Published on: October 4, 2014

17.0K

Related Experiment Videos

Last Updated: Jan 27, 2026

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K
Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection
11:14

Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection

Published on: November 7, 2018

18.8K
Monitoring of Systemic and Hepatic Hemodynamic Parameters in Mice
16:09

Monitoring of Systemic and Hepatic Hemodynamic Parameters in Mice

Published on: October 4, 2014

17.0K

Area of Science:

  • Hepatology
  • Virology
  • Public Health

Background:

  • Hepatitis C virus (HCV) infection is often viewed primarily as a liver disease.
  • However, HCV infection presents significant extrahepatic manifestations and systemic complications.
  • The full impact of HCV is not solely defined by clinical outcomes.

Purpose of the Study:

  • To emphasize the systemic nature of hepatitis C virus (HCV) infection.
  • To advocate for a comprehensive assessment of HCV's burden, including clinical, economic, and patient-reported outcomes.
  • To highlight the societal and individual benefits of curing HCV.

Main Methods:

  • Literature review and synthesis of existing data on HCV's clinical manifestations.
  • Analysis of economic impact studies related to HCV.
  • Review of patient-reported outcome measures in HCV-infected populations.

Main Results:

  • HCV infection is a systemic disease with diverse hepatic and extrahepatic complications.
  • The economic burden of HCV includes direct medical costs and indirect costs like lost productivity.
  • Patient-reported outcomes reveal significant impacts on quality of life.

Conclusions:

  • A holistic understanding of HCV requires integrating clinical, economic, and patient-centered perspectives.
  • Recognizing the multifaceted burden of HCV is essential for appreciating the value of curative therapies.
  • Curing HCV offers substantial benefits to both individual patients and society.